Tevogen Bio (NASDAQ:TVGN) Trading Up 0.9% – Time to Buy?

Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shot up 0.9% on Tuesday . The company traded as high as $1.12 and last traded at $1.09. 181,605 shares were traded during mid-day trading, a decline of 96% from the average session volume of 5,081,068 shares. The stock had previously closed at $1.08.

Analyst Ratings Changes

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Tevogen Bio in a report on Tuesday, March 11th.

Tevogen Bio Stock Down 6.5 %

The business’s 50 day moving average price is $1.32 and its two-hundred day moving average price is $1.24.

Insiders Place Their Bets

In related news, insider Neal Flomenberg sold 232,968 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $1.09, for a total transaction of $253,935.12. Following the sale, the insider now owns 3,595,608 shares in the company, valued at $3,919,212.72. The trade was a 6.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 406,510 shares of company stock valued at $446,763. 56.60% of the stock is currently owned by insiders.

Institutional Trading of Tevogen Bio

A number of hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in Tevogen Bio in the 4th quarter valued at approximately $38,000. JPMorgan Chase & Co. increased its position in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after acquiring an additional 16,695 shares during the period. Barclays PLC raised its stake in shares of Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after acquiring an additional 12,847 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Tevogen Bio during the fourth quarter worth $55,000. Finally, Northern Trust Corp grew its stake in shares of Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after purchasing an additional 13,595 shares during the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.